Biotech Values

[DewDiligence]

Re: Cordaptive

[This is a repost of a prior message with a typo correction in the last sentence.]

>They were titrating-up the Niaspan arm until week 12. Therefore, the Niaspan arm was only on 2gr for 4 weeks while the Cordaptive patients were exposed to 12 weeks.<

Is this really unfair? Isn’t part of the impetus for developing Cordaptive that its proprietary anti-flushing agent allows faster titration? Faster titration presumably means fewer office visits, less early medical intervention, and fewer discontinuations in a real-world setting.

In a long “outcomes” study, the difference in titration speed probably won’t matter much, however.